ReviewCancers2026
Gastric Cancer Biomarkers: From Cellular Identity to Precision Oncology.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric Cancer (GC) is characterized by remarkable biological heterogeneity, reflected by the continuous expansion of biomarkers with diagnostic, prognostic, predictive, and therapeutic relevance. However, most reviews organize these biomarkers according to signaling pathways or individual molecular alterations, often overlooking the interconnected biological processes and functional states that shape gastric carcinogenesis and tumor evolution. This review proposes a biology-oriented conceptual framework that interprets GC biomarkers through five fundamental biological questions capturing interconnected biological capabilities and tumor states: preservation of gastric lineage identity, acquisition of stem cell-like properties, epithelial-mesenchymal transition, immune evasion, and dependence on actionable oncogenic pathways. Within each biological domain, biomarkers were critically selected and comparatively evaluated according to their biological significance, pathological applicability, translational relevance, and clinical utility. Core biomarkers central to each biological process are discussed alongside complementary biomarkers that further refine biological interpretation and clinical stratification. Rather than presenting another comprehensive catalogue of molecular alterations, this review integrates current evidence into a coherent framework linking tumor biology with diagnostic pathology and precision oncology. By emphasizing biological capabilities rather than isolated molecular pathways, this approach provides a practical perspective for biomarker interpretation and establishes a conceptual foundation for future multimarker strategies in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.